Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC

Key facts

Sponsor

Luo Yaping

Principal Investigator

Yaping LUO

Peking Union Medical College Hospital

Intervention

68Ga-DOTA-CCK-FS PET/CT(diagnostic_test)

Enrollment

30 target

Eligibility

All sexes

Timeline

2025 – 2028

Study locations (1)

• Peking Union Medical College Hospital, Beijing, Beijing Municipality, China

Collaborators

Peking Union Medical College Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Medullary thyroid carcinoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07383246
  CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• ENROLLING BY INVITATIONNCT06852144
  PET-TC in Thyroid Evaluation
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• RECRUITINGNANCT06141369
  Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
  Shanghai Jiao Tong University School of Medicine
• RECRUITINGNANCT06277180
  68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
  Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• RECRUITINGPHASE1NCT06520319
  Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
  First Affiliated Hospital of Fujian Medical University
• RECRUITINGPHASE4NCT05830500
  Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• ACTIVE NOT RECRUITINGPHASE1NCT04877613
  GFRα4 CAR T Cells in MTC Patients
  University of Pennsylvania
• ACTIVE NOT RECRUITINGNANCT04522570
  Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
  Instituto do Cancer do Estado de São Paulo

See all trials for Medullary thyroid carcinoma →